FDA recall record

Minivelle recall — FDA D-0923-2017

Defective Delivery System: Out of specification for peel force from the release liner specification during stability testing at 18M 25C/60%RH.

Class IIIclassification
D-0923-2017official record ID
Jul 5, 2017report date

Recall record at a glance

Official recordD-0923-2017
CategoryDrug Recalls
ClassificationClass III
FDA record statusTerminated
Recalling firmNoven Pharmaceuticals, Inc.
Report dateJul 5, 2017
Recall initiation dateApr 27, 2017
Quantity14434 cartons
LocationMiami, FL, United States

Official product description

Minivelle (estradiol Transdermal System) 0.1 mg per day, pack of 8 systems per carton, Rx only, Dist. by: Noven Therapeutics, LLC. Miami, Florida 33186. NDC: 68968-6610-8

Why the product was recalled

Defective Delivery System: Out of specification for peel force from the release liner specification during stability testing at 18M 25C/60%RH.

Distribution information

Nationwide within US

How to read the classification

FDA Class III generally covers situations in which use of or exposure to the product is not likely to cause adverse health consequences. The classification displayed here is taken from the FDA enforcement record.

Additional record details

Recall type: Voluntary: Firm initiated. Initial notification: Letter.

What to do next

If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.

About this record

Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.

FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.

Related recall records

Other records from the same recalling company are shown first when available.

DrugDec 7, 2022

Daytrana recall — FDA D-0071-2023

Defective Delivery System: Recalled lot was found to be out of specification for shear. Shear is an attribute related to the adhesive properties of the transdermal patches.

Class IIFDA: OngoingNoven Pharmaceuticals Inc.
DrugJul 6, 2022

Daytrana recall — FDA D-1169-2022

Defective Delivery System: Customer complaints received for ripping patches and tight release/adhesive transfer.

Class IIFDA: OngoingNoven Pharmaceuticals Inc.
DrugJun 1, 2022

Daytrana recall — FDA D-0889-2022

Defective Delivery System: customer complaints exceeded respective action limits.

Class IIFDA: OngoingNoven Pharmaceuticals Inc.